JE
BCLI

JMAC Enterprises’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

JMAC Enterprises’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,362
Closed -$15.1K – 170
2024
Q3 		$15.1K Hold
4,362
– – ﹤0.01% 180
2024
Q2 		$22.1K Hold
4,362
– – ﹤0.01% 173
2024
Q1 		$36.9K Hold
4,362
– – 0.01% 167
2023
Q4 		$17.9K Hold
4,362
– – ﹤0.01% 169
2023
Q3 		$13.1K Buy
4,362
+1,667
+62% +$37.9K ﹤0.01% 160
2023
Q2 		$83.3K Hold
2,695
– – 0.02% 170
2023
Q1 		$133K Hold
2,695
– – 0.03% 174
2022
Q4 		$66.3K Hold
2,695
– – 0.02% 173
2022
Q3 		$179K Sell
2,695
-334
-11% -$16.8K 0.05% 169
2022
Q2 		$125K Hold
3,029
– – 0.03% 175
2022
Q1 		$153K Hold
3,029
– – 0.04% 175
2021
Q4 		$144K Buy
+3,029
New +$149K 0.03% 171

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JMAC Enterprises's BCLI Position: Q4 2024 in Review

JMAC Enterprises sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 4,362 shares — an estimated $15.1K sold.

JMAC Enterprises first reported a position in BCLI in Q4 2021 and held it in 12 quarters. The position peaked at $179K in Q3 2022. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • JMAC Enterprises reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • JMAC Enterprises sold 4,362 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $15.1K.
  • JMAC Enterprises first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2021 and held it in 12 quarters.
  • JMAC Enterprises's BRAINSTORM CELL THERAPUTC position peaked at $179K in Q3 2022.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on JMAC Enterprises's 13F filing for Q4 2024, filed 29 Jan 2025.